Susan Benton

Susan Benton joined the Ocuphire Board in November 2020. She serves as the General Manager and Head of the U.S. for Thea Pharma, Inc., a wholly owned subsidiary of Thea Laboratories, a leading independent ophthalmic pharmaceutical company, since 2019. Ms Benton has extensive experience in building companies and brands with deep expertise in strategy, commercial operations, and business development. Ms. Benton’s career spans more than 30 years in life sciences with over 20 years focused in ophthalmology. From 2015-2019, Susan served in a number of key leadership positions while at Shire and played an instrumental role in the expansion of the ophthalmic pipeline. As the Head of New Products, she led the Ophthalmic Innovation Committee that shaped and executed the growth strategy for the franchise. Before joining Shire, Susan served in a leadership capacity in Global Business Development for Bausch + Lomb Pharmaceuticals where she and the Corporate Development team transacted over 10 deals in 3 years. She was a co-Founder and CCO for an ophthalmic start-up, Sirion Therapeutics, where she launched and oversaw the commercialization of Durezol